Study summary
An antibody against antibody-making plasma cells raised platelets in 91% at the top dose
91%platelet response at 600 mg, vs 23% with placebo
What was tested
Mezagitamab, an anti-CD38 antibody injected weekly for 8 weeks that removes plasma cells making anti-platelet antibodies, against placebo, in chronic ITP.
What they found
- Platelet response through week 16: 10 of 11 (91%) at 600 mg vs 3 of 13 (23%) with placebo.
- Side effects were similar to placebo.
What it means
Led to the phase 3 trial now under way.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.